BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, June 4, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 28, 2020
View Archived Issues
Epigenetic resistance to PARP inhibitors
Read More
Microglial pruning under the influence links alcohol to anxiety
Read More
Hoth reports research findings on ability of HT-003 to block acne pathogenic gene expression
Read More
Australian researchers uncover critical aspects of MR1 protein to boost immune system
Read More
FDA clears IND application for ANK-700
Read More
Shouyao Holdings describes new FGFR-4 inhibitors
Read More
New baculoviral IAP repeat-containing protein 5 inhibitors patented by Trillium Therapeutics
Read More
Popular opinion correct on fear, anxiety
Read More
Pivotal phase III CheckMate-274 study of Opdivo meets primary endpoints
Read More
FDA clears new IND for ADXS-504
Read More
Voronoi synthesizes new dual specificity protein kinase TTK inhibitors
Read More
Sichuan Kelun-Biotech Biopharmaceutical discovers PRMT5 inhibitors
Read More
IL-20 blockade can be a promising treatment for PDAC, synergizing with anti-PD-1 therapy
Read More
New phosphatidylserine synthase inhibitors disclosed by Daiichi Sankyo
Read More
Enhertu approved in Japan for HER2-positive metastatic gastric cancer
Read More
Novavax initiates U.K. phase III study of NVX-CoV2373 COVID-19 vaccine candidate
Read More
Japan first to approve Ecclock for primary axillary hyperhidrosis
Read More
Clinical activity seen with SNS-301 and pembrolizumab in head and neck cancer trial
Read More
Serum Fetuin-B as potential biomarker of metabolic syndrome and insulin resistance
Read More
Phase II trial reveals activity of retifanlimab in chemotherapy-naive Merkel cell carcinoma
Read More
FDA approves Nucala for hypereosinophilic syndrome
Read More
Basilea initiates phase I/II study of derazantinib in advanced gastric cancer
Read More
Ayvakyt approved in E.U. for unresectable or metastatic PDGFRA D842V mutant GIST
Read More
Jyseleca receives E.U. approval for moderate to severe active rheumatoid arthritis
Read More
Lenvatinib effective in combo with pembrolizumab in PD-L1-refractory melanoma
Read More
FDA clears IND for phase II study of Stemedica's itMSCs for COVID-19
Read More
ImmVira studies T-3011 in phase I for advanced cutaneous or subcutaneous malignancies
Read More
